

COMPANY ANNOUNCEMENT

CTA to undertake first patient trials with new anticancer agent

14th March 2008, Melbourne, Australia. Cancer Trials Australia (CTA) announced today that it had entered into an agreement with Bristol-Myers Squibb Company (NYSE:BMJ) to conduct a first time in patient study (FTIH) using new protocols developed by CTA for the CTN regulatory guidelines.

“This agreement has required cooperation with the global development leaders in the USA and the local clinical trial managers and we are very pleased to have gained their confidence to conduct the study,” said Mark Rosenthal, Chairman of CTA and Professor of Oncology at Royal Melbourne.

Bristol-Myers Squibb and CTA are planning to conduct this study using four clinical sites, with a plan to start in early 2008.

About Cancer Trials Australia (CTA)

CTA is a not-for-profit Clinical Site Advisory Organisation providing research governance, advisory and laboratory assay services to investigators and sponsors of clinical trials in the field of oncology. Its member organisations are:

Austin Health
Ludwig Institute for Cancer Research
Melbourne Health
Peter MacCallum Cancer Centre
The Walter and Eliza Hall Institute
Western Hospital

For further information please contact:

Mr Marcus Clark, Chief Executive Officer CTA 03 9342 7306.